Drugs / CILMOSTIM
CILMOSTIM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02965664 | Dec 2016 → Apr 2017 | presbyopia | Orasis Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02745223 | Jul 2016 → Jun 2017 | presbyopia | Orasis Pharmaceuticals Ltd. | Completed | No outcome recorded |
Press releases naming this drug 6 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CILMOSTIM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108239 ↗ |
| Known as | CSF-1 | “PresbiDrops (CSF-1) is a topical ophthalmic drug.” NCT02745223 ↗1“PresbiDrops (CSF-1) is a topical ophthalmic drug.” NCT02965664 ↗ |
| Known as | M-csf | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108239 ↗ |
| Known as | PresbiDrops | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02965664 ↗ |
| Known as | Rhm-csf | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108239 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108239 ↗ |
| Route | Topical | “PresbiDrops (CSF-1) is a topical ophthalmic drug.” NCT02745223 ↗ |